Patients whose metastatic colorectal cancer is refractory to standard therapies benefit from a new combination agent TAS-102 after it was found to improve the overall survival compared to placebo, a new study presented at the ESMO 16th World Congress on Gastrointestinal Cancer in Barcelona reveals. "Around 50% of patients with colorectal cancer develop metastases but eventually many of them do not respond to standard therapies," said Takayuki Yoshino of the National ...
Read More
No comments:
Post a Comment